Clinical trial · Observational
Development and Prospective Validation of a Pathology-Based Artificial Intelligence Model for Predicting the Time to Castration Resistance of Prostate Cancer
NCT07376057CI-TRIAL-00101952not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this predictive test is to prospectively test the performance of pre-developed artificial intelligence (AI) predictive model for predicting the time to castration resistance of prostate cancer. Investigators had developed this AI model based on deep learning algorithms in preliminary research, and it performed well in retrospective tests.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Neoplasms, Castration-Resistant | Prostate Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Artificial intelligence (AI)-based predictive model (developed) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients undergo prostate biopsy
- description
- Patients undergo prostate biopsy and are diagnosed with prostate cancer, who receive Hormone therapy.
- interventionNames
- Other: Artificial intelligence (AI)-based predictive model (developed)
Primary outcomes (1)
- measure
- C-index (Concordance Index)
- timeFrame
- For each enrolled patient, the predictive results of AI model will be obtained in not long after prostate biopsy, and the C-index of the AI model will be evaluated through study completion, an average of 3 year.
- description
- The proportion of all patient pairs in which the predicted outcome order matches the actual outcome order. It estimates the probability that the predicted results are consistent with the observed outcomes.
Secondary outcomes (2)
- measure
- sensitivity
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients are diagnosed with intermediate- to high-risk prostate cancer; undergo prostate biopsy 2. Patients only received endocrine therapy for prostate cancer; 3. Patients with complete clinical and pathological information. 4. Patients agree to participate in this diagnostic test. Exclusion Criteria: 1. Patients with other tumors and undergo systemic therapy . 2. The patient refused to participate in this diagnostic test.
References
Publications (0)
Data not yet available
No reference posted for this study.